利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1382 条记录 (耗时 0.072 秒)

    COMPOUND
    95.
    发明申请
    COMPOUND 有权
    复合

    公开(公告)号：US20110136879A1

    公开(公告)日：2011-06-09

    申请号：US12897510

    申请日：2010-10-04

    申请人： George Kokotos ,  Berit Johansen ,  Victoria Magrioti ,  Michael Tsakos

    发明人： George Kokotos ,  Berit Johansen ,  Victoria Magrioti ,  Michael Tsakos

    IPC分类号： A61K31/426 ,  C07D277/24 ,  C07D277/56 ,  C07D277/64 ,  A61K31/428 ,  A61P29/00 ,  A61P17/06 ,  A61P19/02 ,  A61P17/00 ,  A61P17/08 ,  A61P25/00 ,  A61P1/04 ,  A61P1/00 ,  A61P9/00

    CPC分类号： C07D277/64 ,  A61K31/421 ,  A61K31/423 ,  A61K31/426 ,  A61K31/428 ,  C07D277/24 ,  C07D277/28 ,  C07D277/30 ,  C07D277/56

    摘要： The invention provides compounds of formula (I) wherein X is O or S; R1 is H, OH, SH, nitro, NH2, NHC1-6alkyl, N(C1-6alkyl)2, halo, haloC1-6alkyl, CN, C1-6-alkyl, OC1-6alkyl, C1-6alkylCOOH, C1-6alkylCOOC1-6alkyl, C2-6-alkenyl, C3-10cycloalkyl, C6-10aryl, C1-6alkylC6-10aryl, heterocyclyl, heteroaryl, CONH2, CONHC1-6alkyl, CON(C1-6alkyl)2, OCOC1-6alkyl, or is an acidic group, such as a group comprising a carboxyl, phosphate, phosphinate, sulfate, sulfonate, or tetrazolyl group; R2 is as defined for R1 or R1 and R2 taken together can form a 6-membered aromatic ring optionally substituted by up to 4 groups R5; R3 is H, halo (preferably fluoro), or CHal3 (preferably CF3), each R5 is defined as for R1; V1 is a covalent bond or a C1-20alkyl group, or C2-20-mono or multiply unsaturated alkenyl group; said alkyl or alkenyl groups being optionally interupted by one or more heteroatoms selected from O, NH, N(C1-6 alkyl), S, SO, or SO2; M1 is absent or is a C5-10 cyclic group or a C5-15 aromatic group; and R4 is H, halo, OH, CN, nitro, NH2, NHC1-6alkyl, N(C1-6alkyl)2, haloC1-6alkyl, a C1-20alkyl group, or C2-20-mono or multiply unsaturated alkenyl group, said C1-20alkyl or C2-20alkenyl groups being optionally interupted by one or more heteroatoms selected from O, NH, N(C1-6 alkyl), S, SO, or SO2; with the proviso that the group V1M1R4 as a whole provides at least 4 backbone atoms from the C(R3) group; or a salt, ester, solvate, N-oxide, or prodrug thereof; for use in the treatment of a chronic inflammatory condition.

    摘要翻译： 本发明提供式（I）化合物，其中X是O或S; R1是H，OH，SH，硝基，NH2，NHC1-6烷基，N（C1-6烷基）2，卤素，卤代C 1-6烷基，CN，C 1-6 - 烷基，OC 1-6烷基，C 1-6烷基COOH，C 1-6烷基COOC- C 1-6烷基，C 2-6烯基，C 3-10环烷基，C 6-10芳基，C 1-6烷基C 6-10芳基，杂环基，杂芳基，CONH 2，CONHC 1-6烷基，CON（C 1-6烷基）2，OCOC 1-6烷基，或者是酸性基团， 例如包括羧基，磷酸根，次膦酸根，硫酸根，磺酸根或四唑基的基团; R2如R1或R1和R2所定义，可以一起形成任选被至多4个R 5基团取代的6元芳环; R 3是H，卤素（优选氟）或CHal 3（优选CF 3），每个R 5定义为R 1; V1是共价键或C 1-20烷基，或C 2-20 - 单或多不饱和烯基; 所述烷基或烯基任选地被一个或多个选自O，NH，N（C 1-6烷基），S，SO或SO 2的杂原子中间化; M1不存在或是C5-10环基或C5-15芳基; 和R 4是H，卤素，OH，CN，硝基，NH 2，NHC 1-6烷基，N（C 1-6烷基）2，卤代C 1-6烷基，C 1-20烷基或C 2-20 - 单或多不饱和烯基， C 1-20烷基或C 2-20烯基任选地被一个或多个选自O，NH，N（C 1-6烷基），S，SO或SO 2的杂原子中间化; 条件是V1M1R4基团作为整体从C（R 3）基团提供至少4个骨架原子; 或其盐，酯，溶剂化物，N-氧化物或前药; 用于治疗慢性炎症性疾病。